Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

doi:10.1128/AAC.01102-17

. 2017 Oct 24;61(11):e01102-17.

doi: 10.1128/AAC.01102-17. Print 2017 Nov.

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Wiley A Schell¹, A M Jones², Katyna Borroto-Esoda³, Barbara D Alexander⁴

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
² Computational Genomics Unit, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
³ Scynexis, Inc., Jersey City, New Jersey, USA.
⁴ Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA barbara.alexander@dm.duke.edu.

PMID: 28827419
PMCID: PMC5655100
DOI: 10.1128/AAC.01102-17

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Wiley A Schell et al. Antimicrob Agents Chemother. 2017.

. 2017 Oct 24;61(11):e01102-17.

doi: 10.1128/AAC.01102-17. Print 2017 Nov.

Authors

Wiley A Schell¹, A M Jones², Katyna Borroto-Esoda³, Barbara D Alexander⁴

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
² Computational Genomics Unit, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
³ Scynexis, Inc., Jersey City, New Jersey, USA.
⁴ Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA barbara.alexander@dm.duke.edu.

PMID: 28827419
PMCID: PMC5655100
DOI: 10.1128/AAC.01102-17

Abstract

SCY-078 in vitro activity was determined for 178 isolates of resistant or susceptible Candida albicans, Candida dubliniensis, Candida glabrata, Candida krusei, Candida lusitaniae, and Candida parapsilosis, including 44 Candida isolates with known genotypic (FKS1 or FKS2 mutations), phenotypic, or clinical resistance to echinocandins. Results were compared to those for anidulafungin, caspofungin, micafungin, fluconazole, and voriconazole. SCY-078 was shown to have excellent activity against both wild-type isolates and echinocandin- and azole-resistant isolates of Candida species.

Keywords: Candida; antifungal agents; antifungal resistance.

PubMed Disclaimer

Cited by

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
Jallow S, Govender NP. Jallow S, et al. J Fungi (Basel). 2021 Feb 25;7(3):163. doi: 10.3390/jof7030163. J Fungi (Basel). 2021. PMID: 33668824 Free PMC article. Review.
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.
Arendrup MC, Jørgensen KM, Hare RK, Chowdhary A. Arendrup MC, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02136-19. doi: 10.1128/AAC.02136-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844005 Free PMC article.
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.
Ordaya EE, Clement J, Vergidis P. Ordaya EE, et al. Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20. Mycopathologia. 2023. PMID: 37470902 Free PMC article. Review.
Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.
Wang X, Wang W, Li J, An R, Chen L, Lin J, Xu D, Qiu J, Song W, Patiman M, Ruan H, Wang G, Xue F, Wang X, Luo X, Ruan Q, Shi L, Zhang C, Hu L, Wang S, Shi H, Wang X, Zhang S, Li Y, Lu J, Wang B, Xu H, Ye H, Zhang B, Zhang C, Qian S, Wu Q, Jia W, Li C, Liao Q. Wang X, et al. Infection. 2024 Oct;52(5):1787-1797. doi: 10.1007/s15010-024-02233-w. Epub 2024 Apr 3. Infection. 2024. PMID: 38568411 Free PMC article. Clinical Trial.
Antifungal and anti-biofilm activity of a new Spanish extract of propolis against Candida glabrata.
Fernández-Calderón MC, Hernández-González L, Gómez-Navia C, Blanco-Blanco MT, Sánchez-Silos R, Lucio L, Pérez-Giraldo C. Fernández-Calderón MC, et al. BMC Complement Med Ther. 2021 May 21;21(1):147. doi: 10.1186/s12906-021-03323-0. BMC Complement Med Ther. 2021. PMID: 34020643 Free PMC article.

See all "Cited by" articles

References

1. Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. 2012. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 32:890–901. doi:10.1002/j.1875-9114.2012.01124. - DOI - PubMed
1. Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance programs (2003). J Clin Microbiol 44:1782–1787. doi:10.1128/JCM.44.5.1782-1787.2006. - DOI - PMC - PubMed
1. Costa-de-Oliveira S, Pina-Vaz C, Mendonça D, Gonçalves Rodrigues A. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis 27:365–374. doi:10.1007/s10096-007-0448-4. - DOI - PubMed
1. Pfaller M, Neofyots D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 74:323–331. doi:10.1016/j.diagmicrobio.2012.10.003. - DOI - PubMed
1. Zilberberg MD, Shorr AF, Kollef MH. 2008. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 14:1756–1758. doi:10.3201/eid1411.080337. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. 2012. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 32:890–901. doi:10.1002/j.1875-9114.2012.01124. - DOI - PubMed

[2] Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. 2012. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 32:890–901. doi:10.1002/j.1875-9114.2012.01124. - DOI - PubMed

[3] Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance programs (2003). J Clin Microbiol 44:1782–1787. doi:10.1128/JCM.44.5.1782-1787.2006. - DOI - PMC - PubMed

[4] Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance programs (2003). J Clin Microbiol 44:1782–1787. doi:10.1128/JCM.44.5.1782-1787.2006. - DOI - PMC - PubMed

[5] Costa-de-Oliveira S, Pina-Vaz C, Mendonça D, Gonçalves Rodrigues A. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis 27:365–374. doi:10.1007/s10096-007-0448-4. - DOI - PubMed

[6] Costa-de-Oliveira S, Pina-Vaz C, Mendonça D, Gonçalves Rodrigues A. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis 27:365–374. doi:10.1007/s10096-007-0448-4. - DOI - PubMed

[7] Pfaller M, Neofyots D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 74:323–331. doi:10.1016/j.diagmicrobio.2012.10.003. - DOI - PubMed

[8] Pfaller M, Neofyots D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 74:323–331. doi:10.1016/j.diagmicrobio.2012.10.003. - DOI - PubMed

[9] Zilberberg MD, Shorr AF, Kollef MH. 2008. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 14:1756–1758. doi:10.3201/eid1411.080337. - DOI - PMC - PubMed

[10] Zilberberg MD, Shorr AF, Kollef MH. 2008. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 14:1756–1758. doi:10.3201/eid1411.080337. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Affiliations

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Authors

Affiliations

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources